China's drug ambitions are running into a biological bottleneck

THE PRICE of a cynomolgus monkey in China has climbed past 200,000 yuan (about $29,500) each. The animal, which costs roughly as much as a mid-range electric car, is not a luxury good. It is the workhorse of biomedical research, the creature whose immune system and organs are close enough to humans that regulators demand it before a new drug may touch a patient. Its price is a thermometer. And it is registering fever.

For two decades, from the early 2000s until just before the pandemic, an SPF-grade (specific-pathogen-free) cynomolgus monkey cost between 8,000 and 17,000 yuan. The curve was flat. Then the pandemic shattered it: prices surged to 230,000 yuan in 2022 as COVID vaccine developers competed for animals. When pandemic fever broke, the price fell back to around 80,000 yuan in 2023-24. Now it is climbing again, approaching its previous peak, and this time the driver is not an emergency. It is China's broader pharmaceutical ambition.

The pipeline problem

The reason is not hard to see. China's innovative-drug industry has rebounded with extraordinary ferocity. In 2025, the country recorded more than 5,000 registered clinical trials, including nearly 3,000 involving new drugs, an 18% increase on the year before. Chinese companies signed outbound licensing deals with Western pharmaceutical firms worth $137.7bn that year; in the first half of 2026 alone, 60 deals worth $91bn were announced, 50 of them outbound. The pipeline is swelling in antibody-drug conjugates, bispecific antibodies, cell and gene therapies and small-nucleic-acid drugs-all of which tend to require non-human primates for preclinical toxicology testing. A typical preclinical programme needs around 60 monkeys.

Supply has not kept pace. China currently holds a combined inventory of just over 240,000 of its two main laboratory monkey species, but only about 30,000 are suitable for research use. Breeding facilities in Guangxi, Guangdong and Sichuan provinces report that this year's supply of cynomolgus monkeys has been sold out; the animals are reserved by long-term institutional clients, and no new orders are being accepted. Fewer than 60 facilities nationwide hold the government licence to breed them.

The biological constraint

The bottleneck is biological, not merely logistical. Cynomolgus monkeys reproduce slowly: females give birth to a single offspring, typically once a year. The animal must be at least three years old and pass rigorous pathogen screening before it is acceptable for laboratory research. Expanding breeding capacity, even under ideal conditions, takes years. Some breeders in Sichuan say the oldest monkeys currently available at their facilities are just over two years old.

China cannot simply import its way out of the problem either. Historically, China was the world's dominant exporter of laboratory monkeys, once supplying 50-70% of those imported into the United States before the pandemic. But China halted exports in 2020, ostensibly for biosecurity reasons. The ban has never been lifted. Meanwhile, China's own breeding programme depends on replenishment stock from Southeast Asia-Cambodia, Vietnam, Thailand and Laos-where cynomolgus monkeys are native. That channel was largely discontinued after 2007 and has proved difficult to revive. In March this year the International Union for Conservation of Nature upgraded the cynomolgus monkey to endangered status, tightening CITES (Convention on International Trade in Endangered Species) requirements on cross-border trade.

To be sure, monkey demand is not unique to China. The United States is facing the same shortage. In January this year Charles River Laboratories, the largest American contract research organisation, acquired a Cambodian primate supplier for $510m, one of the most explicit acknowledgements yet that biological supply has become a strategic asset in drug development. American primate imports rose by 30% last year, to nearly 23,000 animals. But China's problem is more acute because it has built one of the world's fastest-growing drug pipelines precisely while cutting itself off from the supply chain it once dominated.

Who wins, who loses

The bottleneck does not affect all players equally. Well-funded pharmaceutical companies can secure monkey supply and CRO capacity in advance; some have acquired entire breeding facilities to guarantee their own pipelines. For them the monkey shortage is a cost, not a roadblock. Smaller biotechs with limited cash reserves must reconsider which programmes to prioritise, and which to abandon. Rising monkey prices are already being woven into the economics of early-stage drug development: for some large-molecule IND (investigational-new-drug) projects that rely heavily on primate testing, quoted preclinical outsourcing costs have exceeded 20m yuan, with monkey procurement potentially accounting for half.

This redistribution of opportunity has a familiar shape. When a shared resource becomes scarce, incumbents with capital and relationships capture it first. Startups are left negotiating from weakness or walking away. The biotech licensing boom has concentrated deal flow among firms that have already proved their pipelines; the monkey squeeze may well do the same.

The deeper question

The monkey shortage also raises a structural question about the global drug-development model. Monkeys remain indispensable because regulators still insist on preclinical safety data from organisms whose biology approximates human response. The FDA's Modernisation Act 2.0 in 2022 removed the old statutory assumption that animal studies were required, and the agency has since signalled that alternative methods, often called new approach methodologies, may reduce or replace animal testing. But progress is slow. For vaccines, gene therapies and advanced biologics, there are still no accepted alternatives to monkeys for studies requiring "complete multiorgan interactions and integrated biology", as the US National Academies put it.

This creates a paradox. The industry wants to develop more innovative drugs faster. It also insists on testing them in animals whose reproduction rate is measured in years, not months. The bottleneck is not an accident of bad planning; it is built into the system.

What to do

Three responses are available, in order of practicality. The first is to expand breeding capacity, both in China and in Southeast Asia. China has few options here: breeding licences are scarce, biosecurity standards are high, and the three-year maturation cycle means any expansion will not bear fruit until the early 2030s at the earliest. The second is to accelerate alternatives. Organ-on-a-chip technology, advanced computational modelling and human-relevant in-vitro assays are improving. They will not replace monkeys entirely, but they may reduce demand enough to ease the squeeze.

The third, and least discussed, is to confront the geopolitical dimension. China's export ban, now six years old, was originally justified by pandemic-era biosecurity. Some researchers suspect it has since acquired a strategic purpose: reserving scarce preclinical resources for domestic use. Whether intentional or not, the ban has the same effect as a subsidy. It tilts competition in favour of Chinese developers at the expense of global scientific co-operation. That would be a mistake for everyone. Drug development is a global enterprise; restricting the flow of research inputs ultimately slows the development of medicines that could benefit patients everywhere.

The monkey shortage is not merely a cost problem. It is a signal that China's biotech ambitions have moved beyond financing and dealmaking into the constraints of physical capacity. The animals reproduce slowly. The regulators demand them. The pipeline is growing faster than biology allows. Someone, somewhere, will have to wait.